Spero Therapeutics (SPRO) Payables (2016 - 2026)

Spero Therapeutics (SPRO) has reported Payables for 11 consecutive years, with $155000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 80.13% year-over-year to $155000.0; the trailing twelve-month figure through Jun 2026 stood at $155000.0 (down 80.13% YoY), and the FY2025 full-year result was $693000.0, down 90.51% from the prior year.
• Payables slipped to $155000.0 in Q2 2026 per SPRO's latest filing, from $217000.0 in the prior quarter.
• Across five years, Payables topped out at $7.3 million in Q4 2024 and bottomed at $155000.0 in Q2 2026.
• Historically, Payables has averaged $2.2 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Payables soared 452.13% in 2024, then slumped 90.51% in 2025.
• Over 5 years, Payables stood at $617000.0 in 2022, then surged by 123.34% to $1.4 million in 2023, then soared by 430.19% to $7.3 million in 2024, then tumbled by 90.51% to $693000.0 in 2025, then sank by 77.63% to $155000.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $155000.0, $217000.0, and $693000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.